210 related articles for article (PubMed ID: 21393426)
21. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo.
Lin J; Huo R; Wang L; Zhou Z; Sun Y; Shen B; Wang R; Li N
Cancer Immunol Immunother; 2012 May; 61(5):677-87. PubMed ID: 22048717
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
23. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
Bühler H; Hoberg C; Fakhrian K; Adamietz IA
In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
25. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
[TBL] [Abstract][Full Text] [Related]
26. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.
Li Y; Wang Z; Kong D; Li R; Sarkar SH; Sarkar FH
J Biol Chem; 2008 Oct; 283(41):27707-27716. PubMed ID: 18687691
[TBL] [Abstract][Full Text] [Related]
27. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
Wilson C; Ottewell P; Coleman RE; Holen I
BMC Cancer; 2015 Feb; 15():55. PubMed ID: 25884855
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
29. CCN1 promotes tumorigenicity through Rac1/Akt/NF-κB signaling pathway in pancreatic cancer.
Wang X; Deng Y; Mao Z; Ma X; Fan X; Cui L; Qu J; Xie D; Zhang J
Tumour Biol; 2012 Oct; 33(5):1745-58. PubMed ID: 22752926
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
Tamura T; Shomori K; Nakabayashi M; Fujii N; Ryoke K; Ito H
Oncol Rep; 2011 Apr; 25(4):1139-43. PubMed ID: 21249320
[TBL] [Abstract][Full Text] [Related]
31. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Sonnemann J; Bumbul B; Beck JF
Mol Cancer Ther; 2007 Nov; 6(11):2976-84. PubMed ID: 18025282
[TBL] [Abstract][Full Text] [Related]
32. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
Fragni M; Bonini SA; Bettinsoli P; Bodei S; Generali D; Bottini A; Spano PF; Memo M; Sigala S
Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):529-38. PubMed ID: 26905520
[TBL] [Abstract][Full Text] [Related]
33. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K
J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891
[TBL] [Abstract][Full Text] [Related]
34. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD; Woodward JK; Lefley DV; Evans CA; Coleman RE; Holen I
Mol Cancer Ther; 2009 Oct; 8(10):2821-32. PubMed ID: 19789217
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells.
Valenti MT; Giannini S; Donatelli L; Realdi G; Lo Cascio V; Dalle Carbonare L
J Endocrinol Invest; 2010 Apr; 33(4):244-9. PubMed ID: 19915386
[TBL] [Abstract][Full Text] [Related]
36. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells.
Nogawa M; Yuasa T; Kimura S; Kuroda J; Segawa H; Sato K; Yokota A; Koizumi M; Maekawa T
Oncol Res; 2005; 15(1):1-9. PubMed ID: 15839301
[TBL] [Abstract][Full Text] [Related]
37. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
39. NSC126188 induces apoptosis of prostate cancer PC-3 cells through inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription.
Won KJ; Kim BK; Han G; Lee K; Jung YJ; Kim HM; Song KB; Chung KS; Won M
Apoptosis; 2014 Jan; 19(1):179-90. PubMed ID: 24085402
[TBL] [Abstract][Full Text] [Related]
40. CCN1/Cyr61-PI3K/AKT signaling promotes retinal neovascularization in oxygen-induced retinopathy.
Di Y; Zhang Y; Nie Q; Chen X
Int J Mol Med; 2015 Dec; 36(6):1507-18. PubMed ID: 26459773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
